EIT Health-supported start-up Leuko has closed a Series A funding of EUR 5 million. The new funding will be used to accelerate clinical trials to obtain regulatory approval in collaboration with leading cancer centres, including Boston Medical Center and MD Anderson in the USA, and Dexeus and Hospital 12 de Octubre in Europe.
Leuko is developing PointCheckTM, the first solution that enables at-home non-invasive white blood cell (WBC) monitoring.
Low WBC levels is one of the most common as well as most devastating and costliest side effects of cancer chemotherapy. Clinical data indicates that as many as one out of every six chemotherapy patients suffer life-threatening infections and hospital readmissions directly linked to low WBCs. At Leuko, we are working on a solution to help patients and providers prevent these hospital readmissions and improve clinical outcomes, by remotely monitoring WBC levels before infections ensue.
Leuko co-founder and CEO Dr. Carlos Castro-Gonzalez
Leuko’s solution, PointCheckTM, is a device that’s connected to the internet which patients simply place their finger on for one minute a day. The device measures WBC levels without the need to draw a blood sample. The data is sent to the patient’s care team, who can triage findings to help patients receive appropriate, preventive treatments under the direction of their clinician. The technology has demonstrated excellent diagnostic accuracy and home usability in recent peer-reviewed studies.
Alongside their goal of obtaining regulatory approval, the new funding from HTH VC, Good Growth Capital, IAG Capital Partners, Nina Capital, and angel investors will continue to help the company pursue its go-to-market and partnership activities with healthcare providers, medical device distributors and pharmaceutical companies.
EIT Health is proud to have supported Leuko on their journey to attract investment. Leuko won the 2021 EIT Health Catapult programme in the Medtech category, as well as two sponsored awards by eg technology and AstraZeneca.